Skip to main content
Premium Trial:

Request an Annual Quote

Predictive Technology Group, Atrin Pharmaceuticals Launch Oncology MDx Collaboration

NEW YORK – Predictive Technology Group and Atrin Pharmaceuticals have partnered to develop molecular diagnostics to expedite improved selection of cancer patients who will benefit from treatment with DNA damage and response (DDR) inhibitors.

The partners plan to develop actionable predictive molecular and companion diagnostics and therapeutics for common disorders and related cancers.

As part of the agreement, to the partners will use Predictive's sequencing capabilities, GenDB databases, and women's health biobank to better understand the clinical spectrum of germline mutations in DDR pathways.

Predictive's technology uses genetic biomarkers to determine whether a woman is at risk of developing endometriosis as well as to diagnose the disease and personalize treatment guidance.

The firms will also examine common gynecologic disorders — including endometriosis — linked to the development of cancers in affected patients. The team aims to improve patient outcomes as well as improvethe safety and clinical efficacy of Atrin's targeted cancer therapeutics and other DDR drug candidates. Atrin plans to use the partnership to further its product pipeline and improve treatments for female cancer patients.

Financial details of the collaboration were undisclosed.

"Following a successful due diligence process, we concluded that Predictive … is the ideal molecular diagnostic partner to help us successfully advance our therapeutic pipeline through clinical development," Atrin CEO and President Oren Gilad said in a statement. "Predictive's portfolio of genomic tests will help us better identify cancer patient populations whose genetic profiles will likely have an optimal clinical response to our proprietary anti-cancer therapeutics."

"We see an opportunity to develop a precision medicine approach to address unmet medical needs by combining our state-of-the-art sequencing capabilities, genomic expertise, and companion diagnostics with Atrin's targeted therapeutics," Predictive CEO and President Bradley Robinson added.